Rapid Feasibility Studies for Novel Routes to Direct CL-20 Intermediates
Award amount
$79,996Program and phase
SBIR · Phase IAward year
2014Award details
- Awarding agency
- Department of Defense
- Branch
- Navy
- Recipient company
- Omm Scientific, Inc
- Proposal award date
- 2014-05-22
- Contract end date
- 2014-11-21
- UEI
- DM23ABHM6JK1
- Solicitation number
- 2014.1
- Topic code
- N141-017
Research abstract
Technology keywords
Not reported
Other awards by this recipient
Verified by the same UEI. These are other public SBIR/STTR award pages, not a merged company record.
- Selective Oxidation of Heterocyclic Amines
- Development of a Broad Spectrum Antiviral for Ebola and Marburg viral Infections
- TOPIC 323 PHASE I; DEVELOPMENT OF RADIATION MODULATORS FOR USE DURING RADIOTHERAP
- Selective Oxidation of Heterocyclic Amines
- SBIR TOPIC 255, PHASE I: DEVELOPMENT OF ANTICANCER VATPASE INHIBITORS
Awards with the same topic code
Verified by an exact topic code match. This is not a text-similarity match.
- Environmentally Friendly Alternative Synthesis and Process to Manufacture Cost-Effective Hexanitrohexaazaisowurtzitane (CL-20)
- Environmentally Friendly Alternative Synthesis and Process to Manufacture Cost-Effective Hexanitrohexaazaisowurtzitane (CL-20)
- Environmentally Friendly Alternative Synthesis and Process to Manufacture Cost-Effective Hexanitrohexaazaisowurtzitane (CL-20)
- Environmentally Friendly Alternative Synthesis and Process to Manufacture Cost-Effective Hexanitrohexaazaisowurtzitane (CL-20)
- Environmentally Friendly Alternative Synthesis and Process to Manufacture Cost-Effective Hexanitrohexaazaisowurtzitane (CL-20)
Research funding history
9 SBIR/STTR records share this UEI (2007–2016). Reported award amounts total $2,584,560. Reported amounts are not federal obligations.
Phases: Phase I, Phase II
Agencies: Department of Health and Human Services, Department of Defense